Generic competition · all medicines · read 12 November 2026
Is there a generic of Carboplatin, and who makes it?
Carboplatin appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 11 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 1.3 and 15.6 years after the first brand approval. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Carboplatin appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 11 generic makers listed as marketed across them.
- 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Where both are dated, the first generic approval came between 1.3 and 15.6 years after the first brand approval.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Injectable, Intravenous
Four or more generic makers listed
Every brand product here is listed as discontinued. 11 generic makers with 41 generic products listed as marketed; the first generic approval is dated 14 October 2004.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Hospira Inc | 14 October 2004 | 4 |
| Pharmachemie Bv | 14 October 2004 | 4 |
| Hikma Pharmaceuticals Usa Inc | 15 October 2004 | 4 |
| Fresenius Kabi Usa Llc | 15 February 2006 | 2 |
| Teyro Labs Private Ltd | 18 January 2007 | 4 |
| Sandoz Inc | 8 May 2008 | 3 |
| Sun Pharmaceutical Industries Ltd | 19 September 2008 | 3 |
| Epic Pharma Llc | 29 July 2009 | 4 |
| Eugia Pharma Specialities Ltd | 28 March 2016 | 4 |
| Accord Healthcare Inc | 9 February 2017 | 5 |
| Gland Pharma Ltd | 15 February 2017 | 4 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Injectable, Injection
Nothing listed as marketed
Every brand product here is listed as discontinued. No generic is listed as marketed (24 generic products listed as discontinued).
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Solution, Intravenous
Brand listed, no generic listed as marketed
Brand listed as marketed: Kyxata. No generic is listed as marketed.
Patents and exclusivities still listed
- 1 April 2045Patent 12427104 drug product
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.